Wuxi Biologics plans to invest US$60 million in establishing a state-of-the-art biologics manufacturing facility in Singapore.
The manufacturing facility will be arranged with single-use bioreactors at the next-generation facility. It is majorly designed to support continuous bio-processing.
Next-generation manufacturing technology is to be deployed in the Singapore facility. The company will install bio-processing capabilities for early-stage development.
The company will install up to 4,500L bioreactor capacity at the facility, including two 2,000L traditional fed-batch and one 500L perfusion based continuous processing.
WuXi’s new facility will engage in both clinical and small volume commercial production. It will also include an early-stage bioprocess development lab.
The facility will create around 150 new jobs.
It is expected to be operational by 2022 and will boast 10 facilities with a total bioreactor capacity of 222,700 L.
The facility uses disposable, modular and continuous technology, which is easier to replicate globally than traditional tech and uses lower capex.
|Wuxi Biologics Global Solution Provider
|To be operational by 2022